Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

[1]  P. Kantoff,et al.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Golfinos,et al.  Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. , 2012, International journal of radiation oncology, biology, physics.

[3]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Chih-Hsin Yang,et al.  Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Michael Thomas,et al.  Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[7]  E. Van Cutsem,et al.  AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Kerbel,et al.  Mouse models of advanced spontaneous metastasis for experimental therapeutics , 2011, Nature Reviews Cancer.

[9]  N. Petrelli,et al.  Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Van Cutsem,et al.  Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Carmeliet,et al.  Lessons from the adjuvant bevacizumab trial on colon cancer: what next? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Ricci-Vitiani,et al.  Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.

[13]  Tracy T Batchelor,et al.  Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. , 2011, Cancer research.

[14]  H. Hollema,et al.  VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. , 2011, Cancer research.

[15]  Rong Wang,et al.  Glioblastoma stem-like cells give rise to tumour endothelium , 2010, Nature.

[16]  Aristotelis Tsirigos,et al.  The autophagic tumor stroma model of cancer or “battery-operated tumor growth” , 2010, Cell cycle.

[17]  Yoon-Jin Lee,et al.  Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. , 2010, Cancer research.

[18]  K. Kelly,et al.  Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. , 2010, Cancer research.

[19]  S. Barni,et al.  Progression of intramedullary metastasis during perioperative cessation of sunitinib , 2010, Nature Reviews Urology.

[20]  A. Oza,et al.  ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC) , 2010 .

[21]  E. Rofstad,et al.  Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination , 2010, International journal of cancer.

[22]  Dae-Ho Lee,et al.  The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. , 2010, Japanese journal of clinical oncology.

[23]  J. Wisoff,et al.  Bevacizumab in recurrent high-grade pediatric gliomas. , 2010, Neuro-oncology.

[24]  L. Ellis,et al.  Is there really a yin and yang to VEGF-targeted therapies? , 2010, The Lancet. Oncology.

[25]  R. Schilsky,et al.  Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Yan Sun,et al.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. , 2010, The Lancet. Oncology.

[28]  Nasser Altorki,et al.  Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Shah,et al.  AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Kantoff,et al.  A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Monk,et al.  Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Kern,et al.  Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  I. Kasman,et al.  Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy , 2010, Clinical Cancer Research.

[34]  Carl V Hamby,et al.  Molecular Imaging of Changes in the Prevalence of Vascular Endothelial Growth Factor Receptor in Sunitinib-Treated Murine Mammary Tumors , 2010, Journal of Nuclear Medicine.

[35]  Mallika Singh,et al.  Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models , 2010, Nature Biotechnology.

[36]  R. Kerbel,et al.  Raising the bar for cancer therapy models , 2010, Nature Biotechnology.

[37]  Karl J. Dykema,et al.  Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study , 2010, Molecular Cancer Therapeutics.

[38]  E. Perez,et al.  Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). , 2010 .

[39]  Bruce E. Johnson,et al.  Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). , 2010 .

[40]  A. Grothey,et al.  Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). , 2010 .

[41]  J. S. Rao,et al.  Effects of irradiation on tumor cell survival, invasion and angiogenesis , 2010, Journal of Neuro-Oncology.

[42]  E. Small,et al.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Ravaud,et al.  Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  P. Allavena,et al.  Inflammation-mediated promotion of invasion and metastasis , 2010, Cancer and Metastasis Reviews.

[45]  P. Gutin,et al.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.

[46]  G. Scagliotti,et al.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  L. Ellis,et al.  Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. , 2010, The Lancet. Oncology.

[48]  H. Iwata,et al.  Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer , 2010, Breast Cancer Research and Treatment.

[49]  K. Leong,et al.  Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. , 2010, Trends in molecular medicine.

[50]  N. Nonomura,et al.  Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: A case report , 2010, International journal of urology : official journal of the Japanese Urological Association.

[51]  A. Marshall,et al.  Lost in migration , 2010, Nature Biotechnology.

[52]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  T. Mikkelsen,et al.  Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma , 2010, Journal of Neuro-Oncology.

[54]  R. Ramlau,et al.  Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  S. Lim,et al.  Hypoxic Tumor Cell Modulates Its Microenvironment to Enhance Angiogenic and Metastatic Potential by Secretion of Proteins and Exosomes* , 2010, Molecular & Cellular Proteomics.

[56]  Amir Abdollahi,et al.  Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[57]  G. Fuller,et al.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.

[58]  S. Sleijfer,et al.  It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor–vascular endothelial growth factor receptor pathway in patients with solid malignancies , 2010, Cancer science.

[59]  T. Coleman,et al.  Frequent Dose Interruptions are Required for Patients Receiving Oral Kinase Inhibitor Therapy for Advanced Renal Cell Carcinoma , 2009, American journal of clinical oncology.

[60]  Jochen Herms,et al.  Real-time imaging reveals the single steps of brain metastasis formation , 2010, Nature Medicine.

[61]  M. Chamberlain.  Radiographic patterns of relapse in glioblastoma , 2010, Journal of Neuro-Oncology.

[62]  V. Preedy,et al.  Progression Free Survival , 2010 .

[63]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[64]  N. Ferrara,et al.  Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. , 2009, Trends in pharmacological sciences.

[65]  P. Ingham,et al.  Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model , 2009, Proceedings of the National Academy of Sciences.

[66]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[67]  L. Stalpers,et al.  Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. , 2009, European journal of cancer.

[68]  Jeannette Y. Wick,et al.  An overview of small-molecule inhibitors of VEGFR signaling , 2009, Nature Reviews Clinical Oncology.

[69]  R. Jain,et al.  VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis Formation , 2009, PloS one.

[70]  H. Kalantari,et al.  Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer , 2009, British Journal of Cancer.

[71]  E. Perez,et al.  5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) , 2009 .

[72]  T. Fojo,et al.  Progression-Free Survival Is Simply a Measure of a Drug’s Effect While Administered and Is Not a Surrogate for Overall Survival , 2009, Cancer journal.

[73]  A. Bikfalvi,et al.  Combined targeting of interleukin‐6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness , 2009, International journal of cancer.

[74]  R. Kerbel,et al.  Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy , 2009, Clinical Cancer Research.

[75]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  C. Porta,et al.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.

[77]  K. Hunter,et al.  Preclinical Drug Development Must Consider the Impact on Metastasis , 2009, Clinical Cancer Research.

[78]  J. D. de Groot,et al.  Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[79]  N. Petrelli,et al.  Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  A. Ravaud,et al.  Sequential sorafenib and sunitinib for renal cell carcinoma. , 2009, The Journal of urology.

[82]  R. Bicknell,et al.  Anticancer strategies involving the vasculature , 2009, Nature Reviews Clinical Oncology.

[83]  N. Wolmark,et al.  A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  K. Miller,et al.  Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. , 2009, European urology.

[85]  G. Melillo,et al.  Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[86]  W. Scheithauer,et al.  Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  E. Jonasch,et al.  Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon , 2009, Cancer.

[88]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[89]  J. Grandis,et al.  Targeting Angiogenesis from Premalignancy to Metastases , 2009, Cancer Prevention Research.

[90]  P. Comoglio,et al.  Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. , 2009, The Journal of clinical investigation.

[91]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[92]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[93]  J. Norman,et al.  Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors , 2009, Nature Medicine.

[94]  L. Chirieac,et al.  Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis , 2009, Cancer Prevention Research.

[95]  L. Ellis,et al.  Cancer: The nuances of therapy , 2009, Nature.

[96]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[97]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[98]  A. Falanga,et al.  Thrombosis associated with angiogenesis inhibitors. , 2009, Best practice & research. Clinical haematology.

[99]  Seta Shahin,et al.  A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  Dan M. Jones.  Avastin-Tarceva combination fails in lung cancer , 2009, Nature Biotechnology.

[101]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[102]  P. Kelly,et al.  Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. , 2009, Journal of neurosurgery.

[103]  P. Schöffski,et al.  Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors , 2009, Acta oncologica.

[104]  D. V. van Spronsen,et al.  The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases , 2009, Acta oncologica.

[105]  J. Wood,et al.  Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis , 2009, Molecular Cancer Therapeutics.

[106]  B. Lindgren,et al.  Sequential therapy with sorafenib and sunitinib in renal cell carcinoma , 2007, Cancer.

[107]  E. Perez,et al.  RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  M. Mrugala,et al.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.

[109]  L. Stalpers,et al.  Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme , 2009, BMC Cancer.

[110]  T. Mikkelsen,et al.  Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan , 2009, Journal of Neuro-Oncology.

[111]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[112]  A. Hasso,et al.  The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. , 2008, Surgical neurology.

[113]  K. Aldape,et al.  VEGF Trap induces antiglioma effect at different stages of disease. , 2008, Neuro-oncology.

[114]  Daniel G Haller,et al.  Bevacizumab beyond progression: does this make sense? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[116]  P. Kelly,et al.  High-grade glioma before and after treatment with radiation and Avastin: initial observations. , 2008, Neuro-oncology.

[117]  T. Fojo,et al.  Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. , 2008, The oncologist.

[118]  W. Cacheux,et al.  Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[119]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[120]  R. Jain,et al.  Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib , 2008, Molecular Cancer Therapeutics.

[121]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  I. Tannock,et al.  Sorafenib for Metastatic Renal Cancer: The Princess Margaret Experience , 2008, American journal of clinical oncology.

[123]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[124]  P. Steeg,et al.  Metastasis: a therapeutic target for cancer , 2008, Nature Clinical Practice Oncology.

[125]  B. Rini,et al.  Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. , 2008, The Journal of urology.

[126]  A. Vincent-Salomon,et al.  A “class action” against the microenvironment: do cancer cells cooperate in metastasis? , 2008, Cancer and Metastasis Reviews.

[127]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[128]  K. Kimura,et al.  Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. , 2007, The Journal of clinical investigation.

[129]  J. Christensen,et al.  Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy , 2007, Proceedings of the National Academy of Sciences.

[130]  L. Naldini,et al.  Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. , 2007, Cancer research.

[131]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[132]  E. Lin,et al.  Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo , 2007 .

[133]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  E. Rock,et al.  Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[135]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[136]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[137]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[138]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[139]  G. Semenza,et al.  Regulation of angiogenesis by hypoxia-inducible factor 1. , 2006, Critical reviews in oncology/hematology.

[140]  Holger Gerhardt,et al.  Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.

[141]  P. Steeg.  Cancer biology: Emissaries set up new sites , 2005, Nature.

[142]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[143]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[144]  M. Westphal,et al.  Inhibition of Glioblastoma Angiogenesis and Invasion by Combined Treatments Directed Against Vascular Endothelial Growth Factor Receptor-2, Epidermal Growth Factor Receptor, and Vascular Endothelial-Cadherin , 2005, Clinical Cancer Research.

[145]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  C. Essen.  Radiation enhancement of metastasis: a review , 1991, Clinical & Experimental Metastasis.

[147]  Pieter Wesseling,et al.  Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option , 2004, Clinical Cancer Research.

[148]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[149]  Richard P. Hill,et al.  Acute Hypoxia Enhances Spontaneous Lymph Node Metastasis in an Orthotopic Murine Model of Human Cervical Carcinoma , 2004, Cancer Research.

[150]  M. Blagosklonny,et al.  Antiangiogenic therapy and tumor progression. , 2004, Cancer cell.

[151]  R. Khokha,et al.  Molecular mechanisms of tumor invasion and metastasis: an integrated view. , 2003, Current molecular medicine.

[152]  Tarik Tihan,et al.  The hypoxic response of tumors is dependent on their microenvironment. , 2003, Cancer cell.

[153]  P. Steeg.  Angiogenesis inhibitors: motivators of metastasis? , 2003, Nature Network Boston.

[154]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[155]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[156]  E. Rofstad,et al.  Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. , 2002, Cancer research.

[157]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[158]  E. Rofstad,et al.  Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8 , 2002, British Journal of Cancer.

[159]  R. Hill,et al.  Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. , 2001, Cancer research.

[160]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[161]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[162]  A. McClatchey.  Modeling metastasis in the mouse , 1999, Oncogene.

[163]  K. Hirschi,et al.  Control of angiogenesis by the pericyte: molecular mechanisms and significance. , 1997, EXS.

[164]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[165]  W. Travis,et al.  A Report of Three Cases , 1986 .

[166]  Deborah Shapley,et al.  US National Institutes of Health: New clinical trials , 1982, Nature.

[167]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[168]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.